西南医科大学学报2025，Vol.48Issue(1)：6-10,5.DOI:10.3969/j.issn.2096-3351.2025.01.002
慢性乙型肝炎追求临床治愈之综合优化治疗策略
Comprehensive Optimization of the Therapy in Chronic Hepatitis B for Pursuing Cinical Cure
摘要
Abstract
China is a high prevalence area for chronic Hepatitis B virus(CHB)infection,which has caused significant harm to public health and imposed a substantial economic burden.Due to differences in main transmission routes,genetic backgrounds,and virus genotypes between China and regions like Europe and the United States,more than 80％of hepatocellular carcinoma(HCC)occurrences in China are associated with chronic Hepatitis B(CHB).Additionally,the number of new HCC cases and the number of patients who die from HCC each year in China account for nearly half of the global figures.Antiviral therapy is an important measure to block or delay the progression of HBV-related liver diseases and reduce the occurrence of HCC,and the only indicator that can bring long-term good outcomes for patients is the disappearance of HBsAg.HBsAg loss has become the ideal therapeutic point for chronic HBV antiviral therapy.As the efficacies of antiviral therapy is affected by multiple factors,in order to improve the incidence of HBsAg disappearance with existing antiviral drugs,it is necessary to optimize treatment according to the situation of patients,including advan-tageous patient selection,combination therapy of PEG-IFN and NA,extended therapy,intermittent therapy,and consolidation therapy after HBsAg disappearance.This article discussed the optimal treatment strategy of antiviral therapy for chronic HBV infection in pursuit of HBsAg disappearance,and provided reference for clinical practice.关键词
慢性乙型肝炎/HBsAg消失/临床治愈/抗病毒治疗Key words
Chronic hepatitis B/HBsAg loss/Clinical cure/Antiviral therapy分类
临床医学引用本文复制引用
谢尧,韦欣,李明慧..慢性乙型肝炎追求临床治愈之综合优化治疗策略[J].西南医科大学学报,2025,48(1):6-10,5.基金项目
国家重点研发计划项目(2023YFC2308105) （2023YFC2308105）
北京市卫生健康委高层次公共卫生技术人才建设项目学科带头人(-03-26) （-03-26）
北京市医院管理局临床医学发展专项经费资助项目(XMLX 202127) （XMLX 202127）
北京市医院管理中心"登峰"人才培养计划(DFL20241803) （DFL20241803）
首都健康研发专项(2022-1-2172) （2022-1-2172）
